CLL

TG Therapeutics has started a multi-centre, Phase I trial of the combination of TG-1101 (ublituximab) and TGR-1202 in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).

The trial will be the first to assess the safety and efficacy of the combination of the company’s TG-1101, a new glycoengineered anti-CD20 monoclonal antibody, and TGR-1202 a one per day, PI3K Delta inhibitor.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

In the trial, dosing of TGR-1202 will start at 800mg once a day (or QD) with dose escalation proceeding in a 3+3 design.

The MD Anderson Cancer Center will be the lead centre for the trial, which is entitled ‘A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of TG-1101 (Ublituximab), a novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Novel PI3k Delta Inhibitor, in Patients with B-cell Malignancies’.

"The commencement of this combination study today represents a major milestone for the company and is the beginning of what we expect to be a robust combination clinical programme."

Patients with CLL and NHL whose disease is relapsed from or refractory to prior therapies, including prior anti-CD20 monoclonal antibodies, PI3K Delta inhibitors, and BTK inhibitors, will be enrolled in the trial.

Furthermore, the company has also opened its first expansion cohort in its ongoing single agent Phase I dose escalation trial of TGR-1202.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Additional patients at the 800mg QD dose level will be enrolled in the expansion cohort, and the company said that dose escalation will continue in the trial as a maximum tolerated dose has not been reached.

TG Therapeutics executive chairman and interim CEO Michael Weiss said: "The commencement of this combination study today represents a major milestone for the company and is the beginning of what we expect to be a robust combination clinical programme, which will include our much anticipated combination of TG-1101 with ibrutinib."

The company intends to present detailed pharmacokinetic and safety data for all patients in the ongoing single agent study of TGR-1202 through the 1,200mg QD cohort as well as efficacy data through the 800mg QD dose escalation cohort at the upcoming American Society of Hematology Meeting (ASH) in December 2013.

Image: A high-magnification micrograph of B-cell chronic lymphocytic leukemia. Photo: courtesy of Nephron.